Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a decidedly cold wind blowing about the Pharmalot grounds. Our short person has successfully departed for another day of learning at the local schoolhouse and our official mascot is comfortably snoozing in a corner. This leaves us to focus on the task at hand, which is to forage for interesting items and the like. So time to get cracking. Here are a few tidbits to help on your own quest. Hope all goes well today.

Small biotech companies — most of whom stick to science, not politics — are speaking up about the House Democrats’ drug pricing bill because they are uniquely worried that the policies included in the legislation bill will dry up venture capital funding that drives their industry, STAT writes. In turn, this would make it impossible for other small startups that turn basic research into new medicines to get off the ground. “This bill could have devastating effects on our industry, period. End of discussion,” says Paul Hastings of Nkarta Therapeutics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy